As filed with the Securities and Exchange Commission on August 11, 2023
Registration No. 333-203508
Registration No. 333-210016
Registration No. 333-216373
Registration No. 333-223382
Registration No. 333-229915
Registration No. 333-237034
Registration No. 333-249351
Registration No. 333-255109
Registration No. 333-263649
Registration No. 333-268295
Registration No. 333-270072
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-203508
Post-Effective Amendment No. 1 to Form
S-8 Registration Statement No. 333-210016
Post-Effective Amendment No. 1 to Form S-8 Registration Statement
No. 333-216373
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-223382
Post-Effective Amendment No. 1 to Form S-8 Registration Statement
No. 333-229915
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-237034
Post-Effective Amendment No. 1 to Form S-8 Registration Statement
No. 333-249351
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-255109
Post-Effective Amendment No. 1 to Form S-8 Registration Statement
No. 333-263649
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-268295
Post-Effective Amendment No. 1 to Form S-8 Registration Statement
No. 333-270072
UNDER
THE SECURITIES ACT OF 1933
CHINOOK
THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
94-3348934 |
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
400 Fairview Avenue North, Suite 900
Seattle, WA 98109
(206) 485-7241
(Address, including zip code, and telephone number, including area code, of
registrants principal executive offices)
Oncologic,
Inc. 2000 Long-Term Incentive Plan
Triton BioSystems, Inc. 2001 Equity Incentive Plan
Aduro Biotech, Inc. 2009 Stock Incentive Plan
Aduro Biotech, Inc. 2015 Equity Incentive Plan
Aduro Biotech, Inc. 2015 Employee Stock Purchase Plan
Chinook 2015 Equity Incentive Plan
Chinook 2015 Employee Stock Purchase Plan
Non-Plan Stock Option Agreement (Inducement Stock Option Award)
Chinook 2019 Equity Incentive Plan
2022 Equity Inducement Plan
(Full titles of the plans)
Karen L. Hale
Chief Legal Officer
Novartis AG
Lichtstrasse
35
4056 Basel
Switzerland
+41 61 324
1111
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Joseph Gilligan
Mahvesh
Qureshi
Gabrielle Witt
Katherine Keeley
Hogan
Lovells US LLP
555 13th Street NW
Washington, DC 20004
(202) 637-5600
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of large accelerated filer,
accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☒ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☐ |
|
Smaller reporting company |
|
☐ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐